UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

Mr. Jose A. Fernandez-Pol
437 Hunters Hill Drive
Chesterfield, MO 63017

COPY MAILED

SEP 1 0 2001

OFFICE OF PETITIONS

In re Application of
J. A. Fernandez-Pol
Application No. 09/784,631
Filed: February 15, 2001
For: Pharmacological Agent and Method of Treatment

FAX RECEIVED

SEP 1 7 2002

PETITIONS OFFICE

Dear Mr. Fernandez-Pol:

You are named as a joint inventor in the above identified United States patent application, filed under the provisions of 35 U.S.C. 118 (United States Code), and 37 CFR 1.47(a), Rules of Practice in Patent Cases. Should a patent be granted on the application you will designated therein as a joint inventor.

As a named inventor, you are entitled to inspect any paper in the file wrapper of the application, order copies of all or any patent thereof (at a prepaid cost per 37 CFR 1.19) or make your position of record in the application. Alternatively, you may arrange to do any of the preceding through a registered patent attorney or agent presenting written authorization from you. If you care to join in the application, counsel of record (see below) would presumably assist you. Joining in the application would entail the filing of an appropriate oath r declaration by you pursuant to 37 CFR 1.63.

Telephone inquiries regarding this communication should be directed to Latrice Bond at (703) 308-6911. Requests for information regarding your application should be directed to the File Information Unit at (703) 308-6911. Information regarding how to pay for and order a copy of the application, or a specific paper in the application, should be directed to Certification Division at (703) 308-9726 or 1 (800) 972-6382 (outside the Washington D.C. area).

Latrice Bond
Paralegal Specialist
Office of Petitions
Office of the Deputy Commissioner
for Patent Examination Policy

Frances Hicks
Lead Petitions Examiner
Office of Petitions
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Thompson Coburn
One Firstar Plaza
St. Louis, MO 63101

Pico/authorship responsibility PTO-Aulakh three
September 3, 2002

Aulakh, Charanjit S.
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:

1. Fernandez-Pol, USA patent 6,441,009, August 27, 2002. Agent and method of preventing and treating heavy metal exposure and toxicity.

SEP 1 / 2002

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner: Aulakh, Charanjit S.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patents, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patents are based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,

Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.
Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com

Pico/authorship responsibility PTO-Aulakh one
September 3, 2002

Aulakh, Charanjit S.
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:

1. Fernandez-Pol, USA patent 6,410,570, June 25, Methods of inactivating a virus and controlling viral replication Examiner: Examiner: Aulakh, Charanjit S.

RECEIVED
SEP 17 2002

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner: Aulakh, Charanjit S.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patent referenced above, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patent is based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,

Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.
Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com

Pico/authorship responsibility PTO-ROTMAN
September 3, 2002

FAX RECEIVED
SEP 17 2002

Rotman, Alan L,
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:


1. Fernandez-Pol, USA patent 6,403,618, June 11, 2002. Agent and method for controlling angiogenesis. Rotman, Alan L, Assistant Examiner: Robinson, Binta.

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner Rotman, Alan L.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patents, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patents are based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,



Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.
Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com

Pico/authorship responsibility PTO-Aulakh two
September 3, 2002

FAX RECEIVED
SEP 17 2002
PETITIONS OFFICE

Aulakh, Charanjit S.
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:

1. Fernandez-Pol, USA Patent 6,407,125, June 18, 2002. Pharmacological agent and method of treatment: Examiner: Aulakh, Charanjit S.

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner: Aulakh, Charanjit S.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patent referenced above, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patent is based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,

Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.

Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com

703 308 6916

*** RX REPORT ***
********** *

RECEPTION OK

TX/RX NO	8049
CONNECTION TEL	
CONNECTION ID	
START TIME	09/17(TU)09:55
USAGE TIME	03'23"
PGS.	6
RESULT	OK